Vaxcyte (PCVX) Is Up 13.2% After Expanding Late-Stage VAX-31 Program And Manufacturing Plans [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
adult OPUS-2 Phase 3 trial, completion of enrollment in the infant Phase 2 dose-finding study, and plans to start the adult OPUS-3 Phase 3 trial in early 2026. A distinctive feature of this update is the breadth of the late-stage program, spanning pneumococcal-naïve adults, previously vaccinated adults, and infants, alongside a sizeable U.S. manufacturing build-out designed to support potential large-scale commercialization. We'll now examine how this expansion of VAX-31's adult and infant Phase 3-ready footprint could influence Vaxcyte's longer-term investment narrative. These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Vaxcyte today, you really have to believe that VAX-31 can turn an early-stage, zero-revenue biotech into a commercial pneumococcal vaccine player, despite ongoing losses and no clear path to profitability in the next few years. The
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech SummitGlobeNewswire
- Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $116.00 price target on the stock.MarketBeat
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 2/2/26 - Form 8-K
- 1/30/26 - Form 424B5
- 1/29/26 - Form 424B5
- PCVX's page on the SEC website